Interferon-induced proteins are elevated in blood samples of patients with chemically or virally induced chronic fatigue syndrome

Immunopharmacology and Immunotoxicology

Volumn 21, Issue 2, 1999, Pages 175-202

  Vojdani, Aristo ^a,b,c   Lapp, Charles W ^d  

^a California   (United States)

^b CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^c Immunosciences Laboratories Inc   (United States)

^d NONE

Author keywords

2 5A Synthetase; Benzene; MTBE; Protein Kinase RNA (PKR); Viruses

Indexed keywords

BENZENE; BETA INTERFERON; BIOCHEMICAL MARKER; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; LEUKOCYTE EXTRACT; PROTEIN KINASE; TERT BUTYL METHYL ETHER;

ADULT; ARTICLE; CELL LINE; CHRONIC FATIGUE SYNDROME; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; ENZYME ACTIVITY; FATIGUE; FEMALE; HUMAN; HUMAN CELL; INTERFERON INDUCTION; MALE; PRIORITY JOURNAL; VIRUS GENOME; VIRUS INFECTION;

EID: 0032916476     PISSN: 08923973     EISSN: None     Source Type: Journal    
DOI: 10.3109/08923979909052757     Document Type: Article

References (62)

1. Fukuda, K; Strause, SE; Hickie, I; Sharpe, MC; Dobbins, JG; Komaroff, AL : The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med 121:953, 1994.
2. Schluderberg, A; Starese, SE; Peterson, P; Blumenthal, S; Komaroff, AL; Spring, SB : NIH conference chronic fatigue syndrome research: definition and medical outcome assessment. Ann Intern Med 177:325, 1992.
3. Komaroff, AL; Buchwald, D : Symptoms and signs of chronic fatigue syndrome. Rev Infect Dis 13:(Suppl. 1):S8, 1991.
4. Holmes, GP; Kaplan, JE; Glantz, NM; Komaroff, AL; Schonberger, LB; Strause, SE; Jones, JF; Dubois, RE; Cunningham-Rundles, C; Pahwa, S; Tosato, G; Zegano, LS; Purtilo, DT; Brown, N; Shcooley, RT; Bris, I : Chronic fatigue syndrome: a working case definition. Ann Intern Med 108:387, 1988.
5. Ablashi, DV : Summary: Viral studies of chronic fatigue syndrome. Clin Infect Dis 18:S130, 1994.
6. Josephs, SF; Henry, B; Balachnadran, N; Strayer, D; Peterson, D; Komaroff, AL; Ablashi, DV: HHV-6 reactivation in three patients with chronic fatigue syndrome. Lancet 337:1346, 1991.
7. Jones, JF; Ray, CG; Minnich, LL; Hick, MJ; Kibler, R; Lucus, DO : Evidence for active Epstein-Barr virus infection in patients with persistent unexplained illnesses; elevated anti-early antigen antibodies. Ann Intern Med 102:1, 1985.
8. Hellinger, WC; Smith, TF; Van Scoy, RE; Spidzor, PG; Forgacs, P; Edson, RS : Chronic fatigue syndrome and diagnostic utility of antibody to Epstein-Barr virus early antigen. JAMA 260:971, 1988.
9. Levy, JA; Greenspan, D; Ferro, F; Lennette, ET : Frequent isolation of HHV-6 from saliva and high seroprevalence of the virus in the population. Lancet 335:1047, 1990.
10. Archard, LC; Bowles, NE; Behan, PO; Bell, EJ; Doyle, D: Post viral fatigue syndrome: persistence of enterovirus RNA in muscle and elevated creatinine kinase. JR Soc Med 81:326, 1988.
11. Miller, NA; Carmichael, HA; Hall, FC; Calder, BD : Antibody to Coxsackie B virus in diagnosing postviral fatigue syndrome. Br Med J 302:140, 1991.
12. DeFreitas, E; Hillard, B; Cheney, P; Bell, DS; Kiggundu, E; Sankey, D; Wroblewska, Z; Palladino, M; Woodward, JP; Koppowski, H : Retroviral sequences related to HTLVII in patients with chronic fatigue immune dysfunction syndrome. Proc Natl Acad Sci 88:2922, 1991.
13. Secchier, P; Zella, D; Crowley, RW; Gallo, RC; Lusso, P : Quantitative PCR for human herpes viruses 6 and 7. J Clin Microbiol 33:2124, 1995.
14. Nicolson, GL; Nicolson, NL : Diagnosis and treatment of mycoplasmal infections in Persian gulf war illness-CFIDS patients. Int J Occup Med Immunol Toxicol 5:69, 1996.
15. Caligiuri, M; Murray, C; Buchwald, D; Levine, H; Cheney, H; Peterson, D et al. : Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome. J Immunol 139:3306, 1987.
16. Morrison, LJA; Behan, WHM; Nehan, PO : Changes in natural killer cell phenotypes with patient with post-viral fatigue syndrome. Clin Exp Immunol 83:441, 1991.
17. Klimas, NG; Salavto, FR; Morgan, R; Fletcher, MA : Immunologic abnormalities in chronic fatigue syndrome. J Clin Microbiol 28:1403, 1990.
18. Lloyd, A; Hickie, I; Hickie, C; Dwyer, J; Wakefield, D : Cell-mediated immunity in patients with chronic fatigue syndrome, healthy control subjects and patients with major depression. Clin Exp Immunol 8:76, 1992.
19. Chao, CC; Janoff, EN; Hu, S; Thomas, K; Gallaghe, M; Tsang, M; et al. : Altered cytokine release in peripheral blood mononuclear cell culture from patients with chronic fatigue syndrome. Cytokine 3:292, 1991.
20. Lloyd, AR; Wakefield, D; Boughton, CR; Dwyer, JM : Immunologic abnormalities in chronic fatigue syndrome. Med J Aust 51:122, 1989.
21. Gin, W; Christiansen, FT; Peter, JB : Immune function and the chronic fatigue syndrome. Med J Aust 51:117, 1989.
22. Vojdani, A; Ghoneum, M; Brautbar, N : Immune alteration associated with exposure to toxic chemical. Toxicology and Industrial Health 8:231, 1992.
23. Heuser, G; Vojdani, A; Heuser, S : Diagnostic markers of multiple chemical sensitivity. In multiple chemical sensitivities addendum to biologic markers in immunotoxicology. National Academy Press, Washington D.C. 117, 1992.
24. Brautbar, N; Vojdani, A : "Multiple chemical sensitivities facts or myth: Toxicology and Industrial Health 8 (Guest Editorial), 1992.
25. Vojdani, A; Campbell, A : Immune functional abnormalities in patients with clinical abnormalities and silicone breast implants. Toxicology and Industrial Health 8:415, 1992.
26. McConnachie, P; Zahalsky, AC : Immune alterations in humans exposed to the termiticide technical chlordane. Arch Env Health 47:295, 1992.
27. Broughton, A; Thrasher, JD; Gard, Z : Immunological evaluation of four arc welders exposed to fumes from ignited polyurethane (isocyanate) foam. Am J Ind Med 13:463, 1988.
28. Denkhaus, W; von Steldem, D; Botzenhardt, U; Konietzho, H : Lymphocyte subpopulations in solvent-exposed workers, Int Arch Occup Environ Health 57:109, 1986.
29. Byers, V; Levin, AS; Ozonoff, DM; Baldwin, RW : Association between clinical symptoms and lymphocyte abnormalities in a population with chronic domestic exposure to industrial solvent-contaminated water supply and a high incidence of leukemia. Cancer Immunol Immunother 27:77, 1988.
30. Haustein, UF; Ziegler, V : Environmentally induced systemic sclerosis-like disorders. Int J Derm 24:147, 1985.
31. Safran, M; Paul, TL; Roti, E; Braverman, LE : Environmental factors affecting autoimmune thyroid disease. Endocrinol Metab Clin North Am 16:327, 1987.
32. Buchwald, D; Garrity, D; Pascualy, R; Kith, P; Ashley, RA; Wener, MH; Kid, PG; Eaton, JW; Ruse, JE : Chronic Fatigue Syndrome. Toxicology Industrial Health 8:157, 1992.
33. Buchwald, D; Garrity, D : Comparison of patients with chronic fatigue syndrome, fibromyalgia, and multiple chemical sensitivities. Arch Int Med 154:2049, 1994.
34. Ziem, G; Done, A : Chronic fatigue, fibromyalgia, and chemical sensitivity: overlapping disorders. Arch Intern Med 154:1913, 1995.
35. Ziem, G; McTamney, J : Profile of patients with chemical injury and sensitivity. Environ Health Perspect 105 (suppl. 2):417, 1997.
36. Vojdani, A; Ghoneum, M; Choppa, PC; Magtoto, L; Lapp, CW : Elevated apoptotic cell population in patients with chronic fatigue syndrome: the pivotal role of protein kinase RNA. J of Int Med 242:465, 1997.
37. Vojdani, A; Mordechai, E; Brautbar, N : Abnormal apoptosis and cell cycle progression in humans exposed to methyl tertiary-butyl ether and benzene contaminating water. Human & Experimental Toxicol 16:485, 1997.
38. Fraser, A; McCarthy, N; Evan, GL : Biochemistry of cell death. Curr Opin in Neurobiol 6:71, 1996.
39. Gerschenson, LE; Rotello, RJ : Apoptosis: a different type of cell death. FASEB J 6:2450, 1993.
40. King, KL; Schwartzman, RA; Cidlowski, JA : Apoptosis in life, death, and the cell cycle. Endocrinol & Metabol 3 (suppl A):93, 1996.
41. Douglas, RG; Martin, SJ : The killer and the executioner: how apoptosis controls malignancy. Curr Opin in Immunol 7:694, 1995.
42. Vaux, DI; Strasser, A : The molecular biology of apoptosis. Proc Natl Acad Sci USA 93:2239, 1996.
43. Bursch, W; Oberhammer, F; Schulte-Hermann, R : Cell death by apoptosis and its protective role against diseases. Tren Pharmacol Sci 13:243, 1992.
44. Ferbus, D; Justesen, J; Besancon, R; Thang, MN : The 2′,5′-oligoadenylate synthetase has a multi-functional 2′,5′-nucleotidyltransferase activity. Biochem Biophys Res Commun 100:847, 1981.
45. Mordechai, E; Kon, N; Henderson, EE; Suhadolnik, RJ : Activation of the interferon-inducible enzymes, 2′,5′-oligoadenylate synthetase and PKR by human T-cell leukemia virus type I Rex-response element. Virol 206:913, 1995.
46. Zhou, A; Hassel, BA; Silverman, RH : Expression cloning of 2-5-dependent Rnase: a uniquely regulated mediator of interferon action. Cell 72:753, 1993.
47. Floyd-Smith, G; Slattery, E; Lengyel, P : Interferon action: RNA cleavage pattern of a (2′-5′)-oligoadenylate dependent endonuclease. Science 212:1020, 1981.
48. nA) in interferon-treated cells. Nucleic Acid Res 9:1571, 1981.
49. nA-dependent ribonuclease. Nature; 289:414, 1991.
50. Salzberg, S; Hacohen, D; David, S; Dovrat, S; Ahwan, S; Gamliel, KH; Birnbaum, M : Involvement of interferon-system in the regulation of cell growth and differentiation. Scanning Microscopy 4:479, 1990.
51. Hubbell, HR; Pequignot, EC, Willis, DH; Lee, C; Suhadolnik, RJ : Differential antiproliferative actions of 2′5′-oligo A trimer core and its cordycepin analog on human tumor cells. International J Cancer 36:389, 1985.
52. 12U) in chronic fatigue syndrome. In Vivo 8:559, 1994.
53. Suhadolnik, RJ; Reichenbach, NL; Hitzges, P; Sobol, RW; Peterson, DL; Henry, B; Ablashi, DV; Carter, WA; Strayer, DR : Upregulation of the 2-5A synthetase/RNase L antiviral pathway associated with chronic fatigue syndrome. Clin Infectious Dis 18 (suppl. 1 S96):104, 1994.
54. Meurs, E; Chong, K; Galabru, J; Thomas, NSB; Kerr, I; Williams, BRG; Hovanessian, AG : Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by Interferon. Cell 62:379, 1990.
55. Hovanessian, AG; Laurent, AG; Chebath, J; Galabru, J; Robert, N; Svab, J : Identification of 69kD and 100kD forms of 2-5A synthetase in interferon treated human cells by specific monoclonal antibodies. EMBO J 6:1273, 1987.
56. Clemens, MJ; Elia, A : The double-stranded RNA dependent protein kinase PKR: structure and function. J. Interferon and Cyto Res 17:503, 1997.
57. Chelbi-Alix, MK; Chousterman, S : Ethanol induces 2′-5′-oligoadenylate synthetase and antiviral activities through interferon-β production. J Biol Chem 267:1741, 1992.
58. Lengyel, P :; Biochemistry of Interferons and their Actions. Annu Rev Biochem 51:251, 1982.
59. Krishnan, L; Baglioni, C : Increased levels of (2′-5′)-oligo(A) polymerase activity in human lymphoblastoid cells treated with glucocorticoids. Proc Natl Acad Sci USA 77:6506, 1980.
60. Besancon, F; Bourgeade, MF; Justesen, J; Ferbus, D; Thang, MN : Two inducers of cell differentiation enhance the 2′5′-oligoadenylate sythetase activity in MSV transformed cells. Biochem Biophys Res Commun 103:16, 1981.
61. Saarma, M; Toots, U; Raukas, E; Zhelkovsky, A; Pivazian, A; Neuman, T : Nerve growth factor induces changes in (2′-5′)-oligo(A) synthetase and 2′-phosphodiesterase activities during differentiation of PC12 pheochromocytoma cells. Exp Cell Res 166:229, 1986.
62. 3 cells. Cell 43:793, 1985.